On November 3, 2025, Sarepta Therapeutics reported that its Phase 3 ESSENCE trial for Duchenne muscular dystrophy therapies AMONDYS 45 and VYONDYS 53 did not meet the primary endpoint, though ...
Zacks Investment Research on MSN
SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure
Sarepta Therapeutics, Inc. SRPT reported third-quarter 2025 adjusted loss of 13 cents per share against the Zacks Consensus ...
The firm's stock tumbled on the news, dropping from $24.45 per share at market close Monday to $15.24 per share when the market opened Tuesday.
Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid ...
Barchart on MSN
Stocks Pressured Amid Valuation Concerns
The Magnificent Seven stocks are under pressure today, weighing on the overall market. Tesla ( TSLA) and Nvidia ( NVDA) are ...
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock fell sharply Tuesday following disappointing results from a key clinical trial and ongoing concerns about its drug pipeline. However, "Pharma Bro" ...
Sarepta Therapeutics shares plunged 37% after two Duchenne muscular dystrophy drugs failed a key trial, raising regulatory ...
Amid historic advances in cell-based therapies and precision medicine, biotech’s biggest challenge isn’t scientific, it’s ...
Sarepta Therapeutics' shares plunged nearly 40% in premarket trading on Tuesday as failure of two of its approved drugs for a ...
Still, CEO Doug Ingram claimed removing the two drugs, Vyondys 53 and Amondys 45, from market would make “little sense” and ...
The ESSENCE trial was intended to prove the efficacy of Vyondys 53 (golodirsen) and Amondys 45 (casimersen), which received ...
Sarepta nevertheless plans to push for full FDA approval of Vyondys 53 and Amondys 45 based on what it said are “encouraging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback